# Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose

**Authors:** Bart A. Jessen, Paul Cornwell, Sean Redmond, Thomas Visalli, Marie Lemper, Todd Bunch, Timothy Hart

PMC · DOI: 10.1007/s00280-023-04595-8 · Cancer Chemotherapy and Pharmacology · 2023-09-29

## Full-text entities

- **Diseases:** Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11420295/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11420295/full.md

---
Source: https://tomesphere.com/paper/PMC11420295